Related Experiment Video
Updated: Dec 31, 2025
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Abstract:
Animal and epidemiologic studies suggest that the use of warfarin might reduce cancer incidence. The antitumor potential of warfarin is demonstrated in different experimental cancer models. Specifically, studies in murine cancer models have shown that warfarin blocks AXL receptor tyrosine kinase by inhibiting a vitamin K-dependent protein called GAS6, thereby may halt the spread of cancer cells. An off-target effect of the anticoagulant warfarin is inhibition of GAS6-AXL signaling, which enhances antitumor immunity and blocks tumorigenesis independently of anticoagulation. Hence, the observed association between warfarin use and lower cancer incidence is likely due to an enhanced antitumor immune surveillance of early cancer. The large observational study also showed a reduction in cancer incidence among regular warfarin users. The study data indicate that warfarin provides a possible cancer protection. Despite some limitations, the results of this study give further support for the hypothesis that warfarin use decreases cancer incidence, which warrants continued investigation. This finding may have important implications for choosing medications in patients who need anticoagulant therapy.
Insights
Warfarin, an anticoagulant medication, may reduce cancer incidence by inhibiting GAS6-AXL signaling, enhancing antitumor immunity. This suggests warfarin offers potential cancer protection, warranting further investigation for patients needing anticoagulation.
Area of Science:
- Oncology
- Pharmacology
- Immunology
Background:
- Animal and epidemiologic studies suggest warfarin use correlates with reduced cancer incidence.
- Warfarin's antitumor potential is observed in experimental cancer models.
- Warfarin inhibits GAS6-AXL signaling, a pathway involved in cancer cell spread.
Purpose of the Study:
- To investigate the potential of warfarin in reducing cancer incidence.
- To explore the mechanisms behind warfarin's observed anticancer effects.
- To evaluate warfarin's impact on antitumor immunity and tumorigenesis.
Main Methods:
- Analysis of animal and epidemiologic studies.
- Examination of warfarin's effect on GAS6-AXL signaling in murine cancer models.
- Observational study assessing cancer incidence in regular warfarin users.
Main Results:
- Warfarin blocks GAS6-AXL signaling, potentially halting cancer cell spread.
- An off-target effect of warfarin enhances antitumor immunity and blocks tumorigenesis.
- A large observational study indicated reduced cancer incidence among regular warfarin users.
Conclusions:
- Warfarin use is associated with a potential reduction in cancer incidence.
- Enhanced antitumor immune surveillance may explain the observed cancer protection.
- Findings support continued investigation into warfarin's role in cancer prevention, with implications for anticoagulant therapy choices.
Related Concept Videos
02:59Cancer Prevention
Some...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Venous Thrombosis III: Interprofessional Care
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...